rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Column Group IV GP, LP

10% owner

Company insider

Files Form 4 as: 10% owner, Eikon Therapeutics; 10% owner, Ngm Biopharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
24
Buys
5
Sells
0
Bought
$52.7M
Sold
$0
Companies
2
Companies where not an officer
2
First trade
26 May 2022
Last trade
3 Sep 2026
Last filed
8 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
EIKN Eikon Therapeutics10% owner · Biotechnology · last 3 Sep 20262 buys · 0 sells
Ngm Biopharmaceuticals10% owner · last 9 Jun 20223 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Sep 2026filed 8 Sep 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$1.0M89,200 at $11.56filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—1,296,629filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$11.4M630,881 at $18.00filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—9,670,000filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—330,000filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—10,467,526filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—357,216filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—827,278filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—28,229filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—5,133,076filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—1,403,568filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—110,928filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—44,249filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—47,898filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—3,785filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Code C—688,283filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$25.9M1,437,323 at $18.00filing
6 Feb 2026filed 9 Feb 2026EIKN Eikon TherapeuticsBiotechnologySEC FORM 4 Bought$892K49,556 at $18.00filing
9 Jun 2022filed 13 Jun 2022Ngm BiopharmaceuticalsSEC FORM 4 Bought$12.8M951,684 at $13.50filing
9 Jun 2022filed 13 Jun 2022Ngm BiopharmaceuticalsSEC FORM 4 Bought$438K32,477 at $13.50filing

Sectors

Health Care2
Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Tim KutzkeyDirector and 10% owner · 10% owner at Eikon Therapeutics, filing Form 4 there in the last year
Roger M. PerlmutterDirector and Officer · Insider at Eikon Therapeutics, filing Form 4 there in the last year
Roy D. BaynesDirector · Chief Medical Officer at Eikon Therapeutics, filing Form 4 there in the last year
Alfred Lloyd Bowie Jr.Chief Financial Officer · Chief Financial Officer at Eikon Therapeutics, filing Form 4 there in the last year
Robert Luther HuffinesDirector · Director at Eikon Therapeutics, filing Form 4 there in the last year